Galway MedTech Disruptor Neurent Medical Secures Oversubscribed Series C to Revolutionize Chronic Rhinitis Treatment

In a landmark achievement for Ireland’s medtech ecosystem, Galway-based innovator Neurent Medical has closed an oversubscribed Series C financing round, securing the capital needed to scale its groundbreaking Neuromark medical device—a game-changing solution for millions suffering from chronic rhinitis worldwide.

The funding round was led by MVM Partners, with substantial backing from Sofinnova Partners, while existing investors EQT Life Sciences, Atlantic Bridge, Fountain Healthcare Partners, and Enterprise Ireland also contributed. In a strategic move, Kyle Dempsey of MVM Partners and Cedric Moreau of Sofinnova Partners will join Neurent’s board of directors, bringing deep expertise in medtech commercialization.

Neurent’s Neuromark device represents a paradigm shift in treating chronic rhinitis through its proprietary Impedance Controlled Radiofrequency technology. This innovative approach precisely targets the overactive posterior nasal nerves (PNN) responsible for the persistent symptoms that plague millions globally—from chronic congestion and nasal obstruction to postnasal drip and sleep disruption.

“We are thrilled to welcome MVM Partners and Sofinnova Partners to the Neurent Medical family,” said Brian Shields, co-founder and CEO. “This Series C financing represents more than capital—it’s validation of our vision to transform how chronic rhinitis is treated. With this support, we’ll accelerate commercial expansion and ensure Neuromark reaches both the physicians who need this tool and the patients desperate for relief.”

The clinical significance of Neurent’s approach cannot be overstated. Traditional treatments for chronic rhinitis—including medications, nasal sprays, and even surgical interventions—often provide limited relief or come with significant side effects. Neuromark’s precision technology offers a minimally invasive alternative that delivers real-time feedback during procedures, giving clinicians unprecedented control and predictability.

“In this rapidly evolving therapeutic category, Neurent has established itself as the gold standard,” noted Kyle Dempsey of MVM Partners. “The proprietary impedance control system provides clinicians with real-time feedback during every procedure, translating to greater treatment confidence, control, and predictability. For patients who’ve exhausted conventional options, this represents genuine hope.”

Cedric Moreau of Sofinnova Partners emphasized the broader potential: “Neurent Medical has developed a truly differentiated approach backed by an expanding body of clinical evidence demonstrating meaningful, durable patient benefit. We see substantial opportunity to expand this platform into additional indications, and we’re honored to partner with Neurent Medical at this pivotal stage of commercial growth.”

The fresh capital injection will fuel multiple strategic initiatives. Neurent plans to dramatically expand patient access across key markets, generate additional clinical evidence across broader patient populations, and continue developing its promising pipeline of therapeutic solutions. This represents not just growth for Neurent, but a significant advancement in addressing a condition that affects quality of life for millions globally.

Brian Shields brings more than technical expertise to Neurent—he’s emerged as a thought leader in Ireland’s startup community. At Silicon Republic’s Founders’ Exchange event in 2025, Shields shared invaluable insights on fundraising strategies and emphasized the critical importance of building exceptional teams. This philosophy has clearly guided Neurent’s trajectory, particularly in establishing its state-of-the-art manufacturing facility in Oranmore.

The Oranmore facility, launched with ambitious plans to create 125 highly skilled jobs by the end of 2028, spans engineering, quality control, operations, supply chain, sales, and marketing functions. This vertical integration strategy positions Neurent to control quality, accelerate innovation, and contribute meaningfully to the regional economy—demonstrating how cutting-edge medtech can drive both healthcare advancement and economic development.

Neurent’s success story reflects the maturation of Ireland’s medtech sector, where academic research, entrepreneurial vision, and strategic investment converge to create globally competitive companies. The company’s ability to attract world-class investors like Sofinnova Partners—which has backed industry giants including NovoCure and Akebia Therapeutics—signals Neurent’s emergence as a serious player in the global medtech landscape.

As Neurent Medical embarks on this next phase of growth, the implications extend far beyond corporate milestones. For the millions suffering from chronic rhinitis—many of whom have found little relief through conventional treatments—Neuromark offers new hope. For Ireland’s medtech ecosystem, Neurent represents another success story that reinforces the country’s reputation as a hub for healthcare innovation.

The convergence of innovative technology, strategic investment, and visionary leadership positions Neurent Medical not just as a company to watch, but as a potential paradigm-shifter in how we approach chronic respiratory conditions. As the company scales its operations and expands access to Neuromark, the healthcare industry will be watching closely to see whether this Galway-based disruptor can indeed transform the standard of care for chronic rhinitis patients worldwide.

medtech #chronicrhinitis #NeurentMedical #Neuromark #healthcareinnovation #GalwayTech #medicaldevices #SeriesC #MVMPartners #SofinnovaPartners #biotechinvestment #medtechstartup #rhinitistreatment #healthcaretechnology #Irishinnovation #medtechfunding #medicaltechnology #digitalhealth #healthtech #medtechnews #SiliconRepublic

game-changing solution millions chronic rhinitis
paradigm shift treating chronic rhinitis
proprietary impedance controlled radiofrequency technology
overactive posterior nasal nerves PNN
transform how chronic rhinitis treated
gold standard rapidly evolving therapeutic category
proprietary impedance control system real-time feedback
clinicians unprecedented control predictability
truly differentiated approach expanding body clinical evidence
meaningful durable patient benefit
dramatic patient access key markets
state-of-the-art manufacturing facility Oranmore
125 highly skilled jobs by end 2028
vertical integration strategy control quality accelerate innovation
maturation Ireland’s medtech sector
serious player global medtech landscape
potential paradigm-shifter approach chronic respiratory conditions
Galway-based disruptor transform standard care chronic rhinitis patients worldwide
healthcare industry watching closely
converge create globally competitive companies
new hope millions suffering chronic rhinitis
limited relief significant side effects
minimally invasive alternative
advance quality of life millions globally
validate vision transform treatment
strategic investment visionary leadership
academic research entrepreneurial vision strategic investment
Ireland’s reputation hub healthcare innovation
healthcare advancement economic development
invaluable insights fundraising strategies
critical importance building exceptional teams
thought leader Ireland’s startup community
landmark achievement Ireland’s medtech ecosystem
oversubscribed Series C financing round
groundbreaking Neuromark medical device
secured capital needed scale
game-changing solution
breakthrough technology
transformative approach
cutting-edge innovation
global healthcare impact
patient-centric design
clinical excellence
precision medicine
healthcare disruption
medical innovation
technology breakthrough
patient relief
medical advancement
investment milestone
commercial expansion
board of directors
strategic partnership
funding success
growth capital
medtech ecosystem
healthcare revolution
nasal nerve ablation
radiofrequency technology
real-time feedback
treatment confidence
clinical evidence
patient benefit
manufacturing facility
highly skilled jobs
regional economy
global markets
pipeline development
therapeutic solutions
quality of life
respiratory conditions
healthcare transformation
medical device innovation
investor confidence
scalability potential
market expansion
technology validation
clinical validation
patient outcomes
medical breakthrough
healthcare investment
startup success
entrepreneurial achievement
innovation leadership
technology commercialization
healthcare accessibility
medical research
patient care
clinical trials
treatment options
healthcare solutions
medical progress
investment opportunity
growth strategy
market opportunity
technology platform
clinical development
patient population
evidence generation
commercialization strategy
healthcare delivery
medical device company
investment round
funding announcement
board appointment
strategic growth
market leadership
technology differentiation
patient access
clinical benefit
manufacturing expansion
job creation
economic impact
healthcare innovation
medical technology
investment success
startup milestone
growth funding
strategic investors
board expansion
technology advancement
patient treatment
clinical progress
healthcare improvement
medical device
investment announcement
funding milestone
growth capital
strategic direction
technology platform
clinical evidence
patient benefit
manufacturing capability
job growth
economic development
healthcare transformation
medical innovation
investment success
startup achievement
growth strategy
market leadership
technology advancement
patient care
clinical development
healthcare delivery
medical progress
investment opportunity
growth potential
market expansion
technology validation
clinical validation
patient outcomes
medical breakthrough
healthcare investment
startup success
entrepreneurial achievement
innovation leadership
technology commercialization
healthcare accessibility
medical research
patient care
clinical trials
treatment options
healthcare solutions
medical progress
investment opportunity
growth strategy
market opportunity
technology platform
clinical development
patient population
evidence generation
commercialization strategy
healthcare delivery
medical device company
investment round
funding announcement
board appointment
strategic growth
market leadership
technology differentiation
patient access
clinical benefit
manufacturing expansion
job creation
economic impact
healthcare innovation
medical technology
investment success
startup milestone
growth funding
strategic investors
board expansion
technology advancement
patient treatment
clinical progress
healthcare improvement

,